DK1133997T3 - Beta-interferon til behandling af immunsygdomme - Google Patents

Beta-interferon til behandling af immunsygdomme

Info

Publication number
DK1133997T3
DK1133997T3 DK01103580T DK01103580T DK1133997T3 DK 1133997 T3 DK1133997 T3 DK 1133997T3 DK 01103580 T DK01103580 T DK 01103580T DK 01103580 T DK01103580 T DK 01103580T DK 1133997 T3 DK1133997 T3 DK 1133997T3
Authority
DK
Denmark
Prior art keywords
interferon
treatment
beta
immune disorders
preparation
Prior art date
Application number
DK01103580T
Other languages
English (en)
Inventor
Serge Braun
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of DK1133997T3 publication Critical patent/DK1133997T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK01103580T 2000-02-23 2001-02-20 Beta-interferon til behandling af immunsygdomme DK1133997T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00440053 2000-02-23
US24608900P 2000-11-07 2000-11-07
EP01103580A EP1133997B1 (en) 2000-02-23 2001-02-20 Beta-interferon for the treatment of immune diseases

Publications (1)

Publication Number Publication Date
DK1133997T3 true DK1133997T3 (da) 2005-04-18

Family

ID=26073631

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01103580T DK1133997T3 (da) 2000-02-23 2001-02-20 Beta-interferon til behandling af immunsygdomme

Country Status (10)

Country Link
US (1) US6906041B2 (da)
EP (1) EP1133997B1 (da)
JP (1) JP2001270840A (da)
AT (1) ATE285253T1 (da)
AU (1) AU780270B2 (da)
CA (1) CA2334520C (da)
DE (1) DE60107888T2 (da)
DK (1) DK1133997T3 (da)
ES (1) ES2234714T3 (da)
PT (1) PT1133997E (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002225870B2 (en) * 2000-11-03 2006-09-21 Intarcia Therapeutics, Inc. Method for short-term and long-term drug dosimetry
CN100434051C (zh) * 2001-08-01 2008-11-19 阿内科瓦有限公司 子宫内装置及其生产方法
DE10148417A1 (de) * 2001-09-29 2003-04-17 Andreas Schwarting Verwendung von Interferon-ß zur Therapie des systemischen Lupus erythematodes
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
CA2499533A1 (en) * 2002-09-26 2004-04-08 Pfizer Products Inc. Use of excipients to increase dna uptake by swine muscle cells
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
HUE031061T2 (en) 2005-01-12 2017-06-28 Biogen Ma Inc The method of transporting interferon-beta
US8716021B2 (en) * 2005-09-07 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of replicators to prevent gene silencing
US20080003202A1 (en) * 2006-03-28 2008-01-03 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
US8114630B2 (en) * 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration

Also Published As

Publication number Publication date
EP1133997A3 (en) 2002-06-05
US6906041B2 (en) 2005-06-14
CA2334520A1 (en) 2001-08-23
ES2234714T3 (es) 2005-07-01
JP2001270840A (ja) 2001-10-02
AU780270B2 (en) 2005-03-10
US20020076399A1 (en) 2002-06-20
DE60107888T2 (de) 2005-12-15
CA2334520C (en) 2008-12-23
EP1133997B1 (en) 2004-12-22
PT1133997E (pt) 2005-04-29
AU2306801A (en) 2001-08-30
ATE285253T1 (de) 2005-01-15
EP1133997A2 (en) 2001-09-19
DE60107888D1 (de) 2005-01-27

Similar Documents

Publication Publication Date Title
NO20031018D0 (no) Oksymorfonpreparater med kontrollert frigivelse
NO20033556L (no) Farmasöytiske formuleringer
NO20035474D0 (no) Prodrugs av GABA-analoger, sammensetninger og anvendelse derav
DK1425001T3 (da) Phenethanolaminderivater til behandling af respiratoriske sygdomme
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
BR0116052A (pt) imidazoquinolinas substituìdas por éter arìlico
BR0214263B1 (pt) processos para a preparaÇço de uma composiÇço para o tratamento dos cabelos.
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
DK1353668T3 (da) Fremgangsmåder til fremstillingen af farmaceutiske sammensætninger, der indeholder epothilonanaloger, til behandlingen af cancer
ATE534381T1 (de) Pharmazeutische cetp-inhibitor-zusammensetzungen
DK1133997T3 (da) Beta-interferon til behandling af immunsygdomme
DK1262236T3 (da) Fremgangsmåde til fremstilling af formet legeme af alfa-alumina
IS7163A (is) Aðferðir til meðhöndlunar á lungnasjúkdómi
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme
DK1492501T3 (da) Fremgangsmåder med anvendelse af lamellare legemer til terapeutiske formål
NO20035352D0 (no) Legemidler for eosinofile sykdommer
DK1390364T3 (da) Aryl-8-azabicyclo[3.2.1]octaner til behandling af depression
ATE303135T1 (de) Pharmazeutische formulierungen zur gesteuerten freisetzung von 4-amino-6,7-dimethoxy-2-(5-
ITRM20030442A0 (it) Composizione farmaceutica (stressen) per il trattamento di iperomocisteinemia.
DK1285659T3 (da) Anvendelse af clarithromycin til fremstilling af et lægemiddel til behandlingen af arthritis deformans
ITDP20020002A1 (it) Dispositivo modulabile per l'attivazione delle arcate dentarie.
FR2819256B1 (fr) Polypeptide induisant des anticorps neutralisant le vih
MA25409A1 (fr) SERINGUE JETABLE AMéLIORéE.
ES1048844Y (es) Cupon precinto desprendible de cajas de medicamentos.
ITTO20000851A0 (it) Composizione farmaceutica per il trattamento della malaria.